Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : University of Miami
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Provectus Biopharmaceuticals Announces License Agreement for Antimicrobial Treatment
Details : Provectus will use the University’s PDAT medical device with RB-PDT for treating bacterial and parasitic infections of the eye.
Brand Name : RB-PDT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : University of Miami
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PV-10 (rose bengal sodium) Percutaneous intralesional injection, which is investigated in combination with standard of care immune checkpoint blockade (CB) for the treatment of advanced cutaneous melanoma.
Brand Name : PV-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 15, 2023
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rose Bengal Disodium,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PV-10 (rose bengal sodium) Percutaneous intralesional injection, which is investigated in combination with standard of care immune checkpoint blockade (CB) for the treatment of Metastatic Uveal Melanoma.
Brand Name : PV-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2023
Lead Product(s) : Rose Bengal Disodium,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Intralesional (IL) administration of PV-10 for the treatment of solid tumor cancers can yield immunogenic cell death within hours of tumor injection, and induce tumor-specific reactivity in circulating T cells within days.
Brand Name : PV-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2021
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Intralesional (IL) (aka intratumoral) administration of PV-10 for the treatment of solid tumor cancers can yield immunogenic cell death and induce tumor-specific reactivity in circulating T cells.
Brand Name : PV-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 21, 2020
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Provectus' Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10 in combination with KEYTRUDA for the treatment of advanced cutaneous melanoma in patients naive to immune checkpoint blockade will be presented at the European Society for...
Brand Name : PV-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 17, 2020
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Presentation highlights clinical trial of PV-10 as a single-agent and in combination with immune checkpoint blockade for the treatment of primary or metastatic tumors of the liver.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2020
Lead Product(s) : Rose Bengal Sodium,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?